Corporate ActionSep 16, 2026, 05:19 PM
Clene Inc. Raises $4M Via Direct Stock Offering
AI Summary
Clene Inc. has announced a registered direct offering of approximately $4.0 million in common stock at a price of $3.28 per share. The offering, which includes participation from existing stockholders, directors, and officers, is expected to close on September 17, 2026. The company intends to use the net proceeds, along with existing cash, for general corporate purposes, primarily to support the regulatory process for its lead drug candidate, CNM-Au8, including filings, expanded access protocols, and manufacturing expansion. The company anticipates these funds will be sufficient to cover operations through mid-first quarter 2027.
Key Highlights
- Clene Inc. announced a registered direct offering of 1,219,513 shares at $3.28 per share.
- The offering is expected to raise approximately $4.0 million in gross proceeds.
- The offering is being made to certain existing stockholders, including directors and officers.
- Proceeds will be used for general corporate purposes, including regulatory filings for CNM-Au8.
- The offering is expected to provide sufficient funding to mid-first quarter 2027.
- The offering is being made without a placement agent, underwriter, broker, or dealer.
Price Impact
More from CLNN